AstraZeneca Beats Q2 Estimates on Strong Cancer Drug Sales

AstraZeneca reported second-quarter 2025 revenue of $14.46 billion, a 12% increase year-over-year, and slightly above analyst estimates of $14.07 billion135.

Oncology (cancer drugs) accounted for 44% of total sales, growing 18% to $6.31 billion in Q213.

Key cancer drugs driving growth included Tagrisso (up 13% to $1.81 billion), Imfinzi (up 27% to $1.46 billion), and Enhertu (up 41% to $666 million)13.

Breast cancer drug Enhertu and Truqap both exceeded expectations, while lung cancer drugs Tagrisso and Imfinzi were among the company's best-sellers3.

AstraZeneca reaffirmed its 2025 outlook and reported ongoing positive momentum in oncology and biopharmaceuticals15.

The company announced the FDA granted Priority Review for Imfinzi in new indications, which may further strengthen future oncology revenues1.

Sources:

1. https://www.benzinga.com/markets/earnings/25/07/46688483/astrazeneca-q2-sales-beat-estimates-on-strong-cancer-drugs-revenues-reaffirms-2025-outlook

3. https://www.biospace.com/business/astrazeneca-ceo-says-world-needs-to-share-in-global-pharma-r-d

5. https://www.businesswire.com/news/home/20250728524655/en/AstraZeneca-results-H1-and-Q2-2025